Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-26401 · 1 trial · 1 indication
Factors ranging from 'not at all' to 'extremely' are used to quantify subjective drug effects
| Arm | Type | Description |
|---|---|---|
| CEP-26401 5 μg, 25 μg, 125 μg, placebo | EXPERIMENTAL | Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.) |
| CEP-26401 5 μg, 25 μg, placebo, donepezil | EXPERIMENTAL | Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.) |
| CEP-26401 5 μg, 125 μg, placebo, modafinil | EXPERIMENTAL | Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.) |
| Name | Type | Description |
|---|---|---|
| CEP-26401 | DRUG | CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg. |
| donepezil hydrochloride | DRUG | Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated |
| modafinil | DRUG | modafinil 200 mg tablet, over-encapsulated |
| Placebo | DRUG | Placebos formulated to match each active drug |
Inclusion Criteria: 1. The subject is able to give legal informed consent and understand the requirements of the study and communicate with the investigator in the local spoken language. 2. The subject is willing to comply with the study requirements (eg, all dietary, exercise, tobacco, and alcohol...
CEP-26401 is an investigational small molecule being developed for the treatment of cognitive impairment. It is in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied for its potential to address cognitive deficits, though its exact mechanism of action has not been disclosed.
CEP-26401 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker symbol TEVA. The drug is currently in Phase 1 clinical development for cognitive impairment, and Teva is the sponsor of the ongoing clinical trial.
CEP-26401 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for cognitive impairment.
CEP-26401 has been studied in one clinical trial, identified as NCT01903824. This was a Phase 1 study titled 'Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects,' which has been completed. The trial enrolled 40 participants and was conducted in the Netherlands.
No alternative names for CEP-26401 have been disclosed. The drug is known only by its developmental code name, CEP-26401, and is being investigated by Teva Pharmaceutical Industries for cognitive impairment. No other names or aliases have been associated with this compound in available information.